CLEARSIDE, XIPERE™ and PEACHTREE to be Front and Center at AAO 2018
- “Suprachoroidal Delivery of CLS-TA for Uveitic Macular Edema: Results of the Phase 3 PEACHTREE Trial”
○ Uveitis Subspecialty Day, in conjunction with the
American Uveitis Society
○ Date and Time:
Saturday, October 27, 2018; 5:06 p.m. CT
- “Phase 3 Efficacy Data of Suprachoroidally Injected CLS-TA for Macular Edema due to Noninfectious Uveitis”
○ AAO General Session, Uveitis Original Paper PA034
○ Date and Time:
Monday, October 29, 2018; 8:30 a.m. CT
“I am honored to have this opportunity to present the PEACHTREE data to my fellow clinicians and researchers and, in so doing, sharing for the first time additional new analyses that I believe provide further support for the already impressive clinical profile of XIPERE in the treatment of uveitic macular edema,” said Dr. Khurana.
XIPERE, Clearside’s first investigational treatment, is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the back of the eye via the suprachoroidal space, or SCS®, which is the space located between the choroid and the outer protective layer of the eye known as the sclera. Clearside’s proprietary suprachoroidal treatment approach is designed to enable rapid dispersion of a high amount of medicine to the back of the eye so that adequate medicine reaches and stays at the site of disease and has potential to act longer. This approach has potential to provide efficacy advantages and require fewer treatments and office visits while minimizing harm to the surrounding healthy parts of the eye.
XIPERE, used either alone or together with an intravitreal anti-VEGF agent, is being studied as part of Clearside’s pipeline of treatments for unmet or underserved sight-threatening eye diseases that manifest in the retina and the choroid.
PEACHTREE, a randomized, masked, sham-controlled Phase 3 trial, enrolled 160 patients with macular edema associated with non-infectious uveitis, comparing XIPERE dosed every 12 weeks to sham control.
The PEACHTREE trial met its primary endpoint, with 47% of patients in the XIPERE arm gaining at least 15 letters in best corrected visual acuity, as measured using the Early Treatment of Diabetic Retinopathy Study scale, from baseline at week 24, compared to 16% of patients in the sham control arm (p<.001). All key secondary and additional endpoints of the PEACHTREE trial were also achieved.
Uveitis, a set of inflammatory conditions affecting the eye, is one the world’s leading causes of blindness. Uveitis occurs in about 350,000 patients in
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Clearside’s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of Clearside’s product candidates, the potential attributes and benefits of Clearside’s product candidates, and the timing of a potential submission of an NDA with the
Chief Financial Officer
Source: Clearside Biomedical, Inc.